Cargando…
Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction
With the gradual prolongation of the overall survival of cancer patients, the cardiovascular toxicity associated with oncology drug therapy and radiotherapy has attracted increasing attention. At present, the main methods to identify early cancer treatment-related cardiac dysfunction (CTRCD) include...
Autores principales: | Xiao, Huiyu, Wang, Xiaojie, Li, Shuang, Liu, Ying, Cui, Yijie, Deng, Xiaoqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631401/ https://www.ncbi.nlm.nih.gov/pubmed/34859069 http://dx.doi.org/10.3389/fcvm.2021.753313 |
Ejemplares similares
-
The Utility of Cardiac Reserve for the Early Detection of Cancer Treatment-Related Cardiac Dysfunction: A Comprehensive Overview
por: Foulkes, Stephen, et al.
Publicado: (2020) -
Anthropometric parameters of obesity can be alternative biomarkers for the potential cardiac dysfunction in obese children
por: Sun, Jing, et al.
Publicado: (2022) -
The role of conventional echocardiographic parameters on detecting subclinical anthracycline therapy related cardiac dysfunction—The SATRACD study
por: Zhang, Wanzhu, et al.
Publicado: (2022) -
Cross-sectional and prospective follow-up study to detect early signs of cardiac dysfunction in obesity: protocol of the CARDIOBESE study
por: Snelder, Sanne M, et al.
Publicado: (2018) -
Secreted Frizzled-Related Protein 5 Protects Against Cardiac Rupture and Improves Cardiac Function Through Inhibiting Mitochondrial Dysfunction
por: Huang, Xin, et al.
Publicado: (2021)